Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp> ‐19, in Subjects With Renal Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID ‐19, in Subjects With Renal Impairment

Published:2022-07-05 Issue:4 Volume:112 Page:892-900
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Toussi Sima S.¹,Neutel Joel Michael²,Navarro Jesus³,Preston Richard Alfred⁴,Shi Haihong⁵,Kavetska Olga⁵,LaBadie Robert R.⁵,Binks Michael⁶^ORCID,Chan Phylinda L.S.⁷,Demers Neil⁵,Corrigan Brian⁵,Damle Bharat⁸^ORCID

Affiliation:

1. Worldwide Research, Development and Medical Pfizer Inc Pearl River New York USA

2. Orange County Research Center Tustin California USA

3. Genesis Clinical Research Tampa Florida USA

4. Division of Clinical Pharmacology, Department of Medicine, Katz Drug Discovery Center, Clinical and Translational Sciences Institute Miller School of Medicine University of Miami Miami Florida USA

5. Global Product Development Pfizer Inc Groton Connecticut USA

6. Worldwide Research, Development and Medical Pfizer Inc Cambridge Massachusetts USA

7. Global Product Development Pfizer Research & Development UK Ltd Sandwich, Kent UK

8. Global Product Development Pfizer Inc New York New York USA

Funder

Pfizer

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2688

Reference25 articles.

1. World Health Organization.WHO coronavirus (COVID‐19) dashboard (2021). Accessed December 9 2021.

2. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

3. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)

4. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19

5. US Food and Drug Administration.Emergency use authorization 091 (Casirivimab and Imdevimab) (2022). Accessed June 30 2022.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019;Bioorganic Chemistry;2024-09

2. Identification, characterization, and in silico ADMET prediction of nirmatrelvir and its degradation products using HPLC‐PDA and LC‐QTOF‐MS/MS;Rapid Communications in Mass Spectrometry;2024-08-26

3. Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice;European Cardiology Review;2024-08-09

4. The anti-COVID-19 drug nirmatrelvir crosses the blood‒brain barrier and exhibits herb–drug pharmacokinetic interactions with Scutellaria baicalensis formulations;Heliyon;2024-08

5. Population pharmacokinetics of nirmatrelvir in Chinese patients with COVID-19: Therapeutic drug monitoring and dosing regimen selection in clinical practice;International Journal of Antimicrobial Agents;2024-08